诺诚健华公司近日宣布，2025年第一季度总收入同比增长129.9%，达到3.8亿元。这主要归功于核心产品奥布替尼的持续放量以及公司与Prolium达成授权许可获得的首付款。据悉，奥布替尼当季收入同比增长89.2%，达到3.1亿元，主要是源于奥布替尼三大适应症，尤其是边缘区淋巴瘤，全部纳入医保后持续放量，以及商业化团队执行能力的不断强化。自身免疫性疾病已成为仅次于肿瘤的全球第二大药物市场，预计到...
Source Link诺诚健华公司近日宣布，2025年第一季度总收入同比增长129.9%，达到3.8亿元。这主要归功于核心产品奥布替尼的持续放量以及公司与Prolium达成授权许可获得的首付款。据悉，奥布替尼当季收入同比增长89.2%，达到3.1亿元，主要是源于奥布替尼三大适应症，尤其是边缘区淋巴瘤，全部纳入医保后持续放量，以及商业化团队执行能力的不断强化。自身免疫性疾病已成为仅次于肿瘤的全球第二大药物市场，预计到...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.